Does Spravato monotherapy approval change anything for IV ketamine clinics?

Mostly it's a regulatory and access change for esketamine specifically. The January 2025 FDA approval allows Spravato to be prescribed as a standalone treatment for treatment-resistant depression rather than only alongside an oral antidepressant. IV ketamine in clinics remains off-label, evidence-supported, and clinician-administered under anesthesia-level monitoring. The two are related cousins but not the same medication or the same delivery model, and the approvals do not transfer between them.

Is at-home oral ketamine considered safe now?

The FDA's October 2023 Drug Safety alert on compounded ketamine for psychiatric use at home still stands, and the 2024-2026 record has produced more, not fewer, safety concerns. The agency has cited cases of respiratory depression and other serious adverse events tied to unmonitored use. Research suggests that on-site clinical monitoring meaningfully changes the safety profile. We are candid with patients: at-home telehealth ketamine is not the same product, the same dose, or the same risk profile as a clinician-administered IV infusion.

What happened with MDMA-assisted therapy?

It was not approved as submitted. In August 2024 the FDA issued a Complete Response Letter to Lykos Therapeutics declining to approve MDMA-assisted therapy for PTSD and requesting an additional Phase 3 trial. The program is being reworked, not abandoned. Late 2025 and 2026 have brought further protocol revisions. We tell patients it is delayed, possibly by years, and that ketamine remains the only legally available, well-studied option in this general space for now.

Has anything changed about who responds to ketamine?

Refinements rather than reversals. Newer 2024-2026 trials and meta-analyses continue to support treatment-resistant depression as the strongest indication. Evidence for suicidal ideation and PTSD continues to grow. The bipolar depression literature remains mixed and warrants careful screening. Pediatric and adolescent data are still limited. None of this changes the basic candidate profile, but it sharpens the conversation we have during your consultation.

Should I wait for newer treatments before trying ketamine?

That's an individual conversation, not a generic answer. If you have treatment-resistant depression and have already tried multiple medications without adequate response, the cost of waiting is real, ongoing depression. MDMA-AT is delayed. Psilocybin is years from FDA review. Newer mechanisms are in early trials. Ketamine has more than two decades of psychiatric use behind it now. Talk with your prescribing provider about your personal timeline and risk tolerance, then decide.

Ketamine Evidence Update 2026: What's New in the Last Year

Why an annual update matters in this field

Ketamine therapy is one of the most actively researched areas in psychiatry and pain medicine. Every twelve months brings new trials, new regulatory actions, new label changes, and the occasional setback. We update this article on the same anniversary each year so patients, referring clinicians, and family members can see what has actually changed and what has stayed the same.

This year's update covers the period from roughly mid-2024 through early 2026. It includes the most consequential FDA actions, the most-cited recent trials and meta-analyses, the regulatory news around MDMA-assisted therapy, and updates from professional societies. Where evidence has shifted, we say so. Where it has not, we say that too.

Ketamine itself is FDA-approved as an anesthetic; its use for depression, anxiety, PTSD, and chronic pain is off-label. Esketamine (Spravato) carries a separate, narrower set of approvals discussed below. None of what follows changes that framing.

Spravato (esketamine) — the January 2025 FDA monotherapy expansion

The biggest regulatory news of the last year was the FDA's January 21, 2025 approval of Spravato (esketamine nasal spray) as a monotherapy for treatment-resistant depression in adults. The original 2019 approval required Spravato to be combined with an oral antidepressant. The 2025 supplemental approval allows it to be used alone, which matters for patients who cannot tolerate oral antidepressants or who simply prefer not to take them.

The approval was based on a Phase 4 randomized, double-blind, placebo-controlled trial. At week 4, 22.5% of patients on esketamine monotherapy achieved remission (defined as a Montgomery-Åsberg Depression Rating Scale score of 12 or lower) compared with 7.6% on placebo. Significant improvement in depressive symptoms was observed within 24 hours of the first dose, consistent with the rapid-onset profile that has defined ketamine-class antidepressants.

It is worth being precise about what this approval does and does not do. It applies to esketamine, the (S)-enantiomer of ketamine, delivered as a nasal spray and administered only at REMS-certified clinics. It does not apply to racemic IV ketamine, the formulation most commonly used in infusion clinics. The 2025 approval also reinforced existing safety language, including the boxed warning around sedation, dissociation, and abuse potential. For a fuller comparison see our piece on ketamine versus Spravato.

The FDA's stance on compounded and at-home oral ketamine

In October 2023 the FDA issued a Drug Safety alert warning about risks associated with compounded ketamine products dispensed for at-home use, citing reports of respiratory depression and other serious adverse events in patients taking these products without on-site monitoring. That alert has not been withdrawn or softened. If anything, the 2024-2026 record has produced more, not fewer, safety concerns.

Several telehealth platforms that grew during the pandemic have quietly narrowed their offerings, paused operations, or come under federal scrutiny over the last 18 months. Compounded oral ketamine remains legal in many states, but the regulatory and clinical consensus is that unmonitored at-home use carries risks that monitored clinic infusions do not. Our broader take on the regulatory landscape lives on the FDA and ketamine page.

We mention this here because it shapes what patients and referring clinicians need to ask. The question is not just "does ketamine work" — research suggests it does for many people with treatment-resistant depression — but "under what conditions can it be delivered safely." Those are different questions, and the 2024-2026 evidence sharpens the answer to the second one.

MDMA-assisted therapy: the August 2024 CRL and the path forward

In August 2024 the FDA issued a Complete Response Letter to Lykos Therapeutics declining to approve MDMA-assisted therapy for PTSD as submitted. The agency requested an additional Phase 3 trial and raised concerns about study conduct, blinding, and the integration of psychotherapy into the regulatory framework. This was the most significant negative regulatory action in psychedelic-assisted therapy in years.

The program has not been abandoned. Lykos has restructured leadership, revised protocols, and signaled an intent to pursue the additional Phase 3 work the FDA requested. A realistic timeline puts any potential approval years away rather than months. We covered the implications in detail in ketamine versus MDMA-assisted therapy.

For patients with PTSD weighing their options, the practical takeaway has not changed. Ketamine remains the only legally available, well-studied option in this general space at present. Evidence supports its use for PTSD symptoms, particularly in combination with psychotherapy. We are honest with patients about the difference between an emerging evidence base and an FDA-approved indication.

New 2024-2026 RCTs and meta-analyses worth knowing

The foundational evidence base for ketamine in treatment-resistant depression still rests on a few anchor studies. Murrough and colleagues, writing in the American Journal of Psychiatry in 2013, conducted a two-site randomized controlled trial of single-dose IV ketamine versus midazolam in 73 patients with treatment-resistant depression and found a 64% response rate at 24 hours with ketamine compared with 28% on midazolam. Wilkinson and colleagues, also in the American Journal of Psychiatry (2018), published an individual participant data meta-analysis confirming rapid acute antidepressant and anti-suicidal effects of single-dose IV ketamine across multiple trials.

The 2024-2026 wave of literature has built on rather than overturned that foundation. Studies indicate that repeated-infusion protocols produce more durable benefit than single doses for many patients, that response is most reliable in treatment-resistant unipolar depression, and that bipolar depression evidence remains mixed. Newer meta-analyses have continued to support short-term efficacy for suicidal ideation, with growing but still limited long-term durability data. PTSD and OCD literatures have expanded but remain smaller than the depression base.

One important nuance: the durability question. Research suggests that without ongoing care — booster infusions, integration work, lifestyle and medication management — single-course benefits often fade over weeks to months. The literature increasingly frames ketamine as a treatment that can open a neuroplastic window rather than a one-time event that resolves a chronic condition.

Practice guideline movement: APA, AANA, and ASKP3

The American Psychiatric Association consensus statement led by Sanacora and colleagues, published in JAMA Psychiatry in 2017, remains the anchor reference for screening, monitoring, and informed consent in U.S. ketamine practice. It has not been formally superseded. Updates and supplemental position papers from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3) and from the American Association of Nurse Anesthesiology have continued to refine clinical standards around dosing, monitoring, and credentialing.

The practical effect on a clinic like ours is incremental rather than dramatic. The expectations have always been straightforward: a CRNA-led model with anesthesia-level monitoring throughout each infusion, screening protocols that exclude patients at elevated cardiovascular or psychiatric risk, and informed consent that makes off-label use explicit. Marla Peterson, CRNA, oversees every infusion at Music City Ketamine and is on-site throughout each session. Those standards have not changed; the supporting documentation in the literature continues to accumulate.

What hasn't changed — and why that matters

It is easy to read an annual update and conclude that the field is in flux. In some ways it is. In the ways that matter most clinically, it is steady.

Treatment-resistant depression remains the strongest indication. The signal across more than a decade of trials is consistent.
Off-label framing has not changed. Ketamine itself is FDA-approved as an anesthetic; its use for psychiatric and pain conditions is off-label. Esketamine has its own narrower approvals.
Anesthesia-level monitoring is still the standard for IV ketamine. Continuous pulse oximetry, blood pressure, and heart rate, with a CRNA in the room. The 2023 FDA alert and the 2024-2026 record have reinforced this.
Cost has not changed materially. Insurance coverage for IV ketamine remains rare. At Music City Ketamine, sessions are $475 each, and we are transparent about that from the first conversation.
The myths persist. Despite the evidence accumulating each year, we still spend time on the same misconceptions: that it is a party drug, that it is addictive in a clinical context the way it can be recreationally, that it replaces traditional psychiatric care. None of those are accurate, and yet they keep showing up.

Steadiness of the core evidence base is a feature, not a bug. It is what allows us to talk honestly with patients about what to expect.

What we're watching for in late 2026 and 2027

A few open questions are likely to shape next year's update. Long-term durability data from extended-protocol studies should continue to mature. Insurance coverage for IV ketamine in treatment-resistant depression may begin to shift as more payers reckon with the comparative effectiveness data. The MDMA-AT program's revised Phase 3 design will be watched closely. Psilocybin for major depressive disorder remains in active Phase 3 development with potential FDA action timelines that vary by sponsor; we discuss the framing in ketamine versus psilocybin.

We are also watching the ongoing FDA scrutiny of compounded ketamine and at-home telehealth models. Whatever happens there will affect the broader perception of the field.

If you are reading this update because you or someone you love is weighing whether to start ketamine therapy, the practical message is that the evidence base in 2026 is more mature, not less, than it was a year ago. Talk with your prescribing provider. Decide based on your situation, not on headlines. Ketamine is not a cure. For the right patient, evidence supports that it may help, sometimes substantially, and the standards for delivering it safely are well established.